No title
Cancer immunotherapy targeting the CD40 receptor on antigen presenting cells (APCs) is a promising treatment strategy that promotes priming of tumor-specific T cells and can revert a suppressive tumor microenvironment. CD40 signaling in dendritic cells (DCs) has been shown to promote maturation, enhance expression of MHC, costimulatory molecules and chemokine receptors, and induce IL-12 secretion,
